Rocket Pharmaceuticals, Inc. officer Martin Wilson filed a Form 144 notice on November 13, 2026, disclosing a proposed sale of 4,087 shares of common stock on NASDAQ:RCKT with an aggregate market value of $9,196.98.

Key Highlights

  • Proposed sale: 4,087 shares of Rocket Pharmaceuticals common stock with an aggregate market value of $9,196.98.
  • Source of shares: The shares were acquired on November 11, 2026, through restricted stock vesting from the issuer as compensation.
  • Approximate sale date: November 13, 2026, through Fidelity Brokerage Services LLC.
  • Shares outstanding: 111,660,283 shares of common stock outstanding at the time of the filing.
  • Tax-related purpose: According to the filing, "Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
  • Prior three-month sales: Wilson sold a combined 132,877 shares in four separate transactions between August 13, 2026, and November 5, 2026, generating gross proceeds totaling $398,237.07.

Wilson's Proposed Sale Follows November 2026 Restricted Stock Vesting

According to the Form 144 filed with the U.S. Securities and Exchange Commission, Martin Wilson, identified as an officer of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), intends to sell 4,087 shares of the company's common stock. The filing states the shares were acquired on November 11, 2026, through restricted stock vesting from the issuer, with the nature of payment listed as compensation. The proposed sale is to be executed through Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917.

The filing notes that the sale includes shares needed to cover a tax obligation arising from the settlement of a vested equity award distribution. The aggregate market value of the proposed sale is listed as $9,196.98. At the time of the filing, the total shares of common stock outstanding were reported as 111,660,283.

The filing also discloses Wilson's sales activity over the prior three months. Four transactions were reported: 3,493 shares sold on August 13, 2026, for gross proceeds of $11,810.18; 631 shares sold on August 18, 2026, for $2,133.66; 75,364 shares sold on September 11, 2026, for $256,486.30; and 53,389 shares sold on November 5, 2026, for $127,807.93. The notice was signed by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Martin Wilson.

What Was Disclosed

Rocket Pharmaceuticals officer Martin Wilson filed a Form 144 on November 13, 2026, noticing a proposed sale of 4,087 shares of common stock valued at $9,196.98, acquired through restricted stock vesting on November 11, 2026, partly to satisfy a tax obligation.